Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that results from the Phase III ...

Adding carboplatin to standard neoadjuvant chemotherapy improves overall survival in TNBC, but the benefit is only ...

Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line treatment in patients with unresectable, locally advanced or ...

Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...

Niraparib significantly improved PFS and time without symptoms for women with advanced ovarian cancer who responded to ...

Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

OptiTROP-Lung04 study showed sac-TMT improved survival in pts with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs, compared with chemotherapy.

In this video, Charu Aggarwal, MD, MPH, the Leslye M. Heisler Professor for Lung Cancer Excellence at University of ...

Immune checkpoint inhibitors have shown efficacy in other HPV-related cancers, so a phase 2 trial tested avelumab treatment for locally advanced or metastatic penile cancer.

Genelux Corp. (($GNLX)) announced an update on their ongoing clinical study. Genelux Corp. is currently conducting a Phase 2 clinical study titled ...

Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...